Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COcoa Supplement and Multivitamin Outcomes Study randomised clinical trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

To examine the long-term effect of cocoa flavanols on inflammaging biomarkers in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS).

Who Took Part

The abstract describes 65 men taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This ancillary study measured five widely used serum inflammaging biomarkers, including three pro-inflammatory markers (high-sensitivity C-reactive protein [hsCRP], interleukin-6, tumour necrosis factor-α), one anti-inflammatory cytokine (interleukin-10) and one pleotropic cytokine (interferon-γ [IFN-γ]) in a random sample of 598 participants with biospecimens collected at baseline, Year 1, and Year 2.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The men were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Neither the men nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some men received a placebo instead of Copper (Supplement), giving a reference point.

What Was Measured

The subject headings attached to it are Age Factors, Aging, Biomarkers, C-Reactive Protein, Cacao, Catechin and Dietary Supplements.

Author keywords: cocoa extract, hsCRP, inflammaging, older adults and randomised controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 65 men.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Age and ageing), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.